學術研究成果/Publication
基本資料/Profiles
姓名/Name: 黃偉謙 性別/Gender:
英文姓名/
English Name:
Huang, Wei-Chien 英文縮寫/
Abbreviation:
任職單位/
Affiliation:
1.藥學院藥學系(教授) / School of Pharmacy(Professor)
2.中國附醫分子醫學中心-訊息傳遞(研究員) / Signal Transduction, Mloecular Medical Center(Research Fellow)
Email: whuang@mail.cmu.edu.tw
研究專長/Fields of Specialty
1﹒ Pharmacology
2﹒ Target therapy
3﹒ Drug resistance
4﹒ Cancer Metabolism
5﹒ Tumor immunology
6﹒ Cancer stem cells
7﹒ Caner epigenetics
8﹒ Cancer Pharmacology
 
期刊論文/Journal Paper
(作者群,論文題目,期刊名稱,出版年月,卷號(期別):頁次起迄)
SCI論文 何建宜(Chien-Yi Ho)、魏湞晏(Cheng-Yen Wei)、趙若雯(Ruo-Wen Zhao)、葉屹綸(Yi-Lun Ye)、黃慧琪(Hui-Chi Huang)、李仁智(Jen-Chih Lee)、鄭方茹(Fang-Ju Cheng)*、黃偉謙(Huang, Wei-Chien)*,Artemisia argyi extracts overcome lapatinib resistance via enhancing TMPRSS2 activation in HER2-positive breast cancer,ENVIRONMENTAL TOXICOLOGY,2024 Feb,():
SCI論文 (Yu-Ying Wu)、(Yat-Yin Law)、(Yu-Wen Huang)、Nguyen Bao T(NGUYEN BAO TRAN)、(Chih-Yang Lin)、(Chao-Yang Lai)、(Yuan-Li Huang)、蔡俊灝(Chun-Hao Tsai)、柯智淵(Chih-Yuan KO)、(Ming-Chih Chou)、黃偉謙(Huang, Wei-Chien)、鄭方茹、馮逸卿(Yi-Ching Fong)*、湯智昕(Chih-Hsin Tang)*,Glutamine metabolism controls amphiregulin-facilitated chemoresistance to cisplatin in human chondrosarcoma,International Journal of Biological Sciences,2023 Oct,19(16):5174-5186
SCI論文 鄭方茹(Cheng, Fang-Ju)、何建宜(Chien-Yi Ho)、李宗勳(Tzong?Shiun Li)、陳曄(Yeh Chen)、葉屹倫(Yeh, Yi-Lun)、魏雅鈴(Ya-Ling Wei)、Huynh Kieu T(Huynh Kieu Thanh)、陳柏融(Chen, Bo-Rong)、(Hung?Yu Ko)、薛晨希(Chen?Si Hsueh)、譚明(Tan, Ming)、吳永昌(Yang-Chang Wu)、黃慧琪(Hui-Chi Huang)、湯智昕(Chih-Hsin Tang)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、黃偉謙(Huang, Wei-Chien)*,Umbelliferone and eriodictyol suppress the cellular entry of SARS-CoV-2,Cell and Bioscience,2023 Jun,13(118):
SCI論文 林良蔚(Lin, Liang-Wei)、(Shih-Wei Wang)、黃偉謙(Huang, Wei-Chien)、(Thanh Kieu Huynh)、(Chao-Yang Lai)、柯智淵(Chih-Yuan KO)、馮逸卿(Yi-Ching Fong)、(Jie-Jen Lee)、(Shun-Fa Yang)*、湯智昕(Chih-Hsin Tang)*,Melatonin Inhibits VEGF-Induced Endothelial Progenitor Cell Angiogenesis in Neovascular Age-Related Macular Degeneration,Cells,2023 Mar,12(5):799
SCI論文 田霓(Ni Tien)、何建宜(Chien-Yi Ho)、賴姝蓉(Lai, Shu-Jung)、(Yu-Chuan Lin)、(Chia-Shin Yang)、(Yu-Chuan Wang)、黃偉謙(Huang, Wei-Chien)*、陳曄(Chen,Yeh)*、張瑞仁(Jui-Jen Chang)*,Crystal structure of the capsular polysaccharide- synthesis enzyme CapG from Staphylococcus aureus,Acta Crystallographica Section F-Structural Biology Communications,2022 Oct,78():
SCI論文 (Kun-Tsan Lee)、蘇錦宏(Su, Chin-Horng)、劉軒誌(Shan-Chi Liu)、(Bo-Cheng Chen)、張郡崴(Chang, Jun-Way)、蔡俊灝(Chun-Hao Tsai)、黃偉謙(Huang, Wei-Chien)、許晉榮(Chin-Jung Hsu)、(Wei- Cheng Chen)、吳永昌(Yang-Chang Wu)、湯智昕(Chih-Hsin Tang)*,Cordycerebroside A inhibits ICAM-1-dependent M1 monocyte adhesion to osteoarthritis synovial fibroblasts,JOURNAL OF FOOD BIOCHEMISTRY,2022 Jul,46(7):e14108
SCI論文 Achudhan Dav(Achudhan David)、張?云(Sunny LY Chang)、劉軒誌(Shan-Chi Liu)、林彥佑、黃偉謙(Huang, Wei-Chien)、吳永昌(Yang-Chang Wu)、黃建中(Huang, Chien-Chung)、蔡俊灝(Chun-Hao Tsai)、柯智淵(Chih-Yuan KO)、郭悅雄(Yueh-Hsiung Kuo)*、湯智昕(Chih-Hsin Tang)*,Antcin K inhibits VCAM-1-dependent monocyte adhesion in human rheumatoid arthritis synovial fibroblasts,Food & Nutrition Research,2022 Jun,66():
SCI論文 (Shang-Yu Yang)、(Chi-Jung Fang)、(Yu-Wen Chen)、(Wan-Ping Chen)、(Li-Ya Lee)、(Chin-Chu Chen)、林彥佑、劉軒誌(Shan-Chi Liu)、蔡俊灝(Chun-Hao Tsai)、黃偉謙(Huang, Wei-Chien)、吳永昌(Yang-Chang Wu)、湯智昕(Chih-Hsin Tang)*,Hericium erinaceus Mycelium Ameliorates In Vivo Progression of Osteoarthritis,Nutrients,2022 Jun,14(13):2605
SCI論文 何建宜(Chien-Yi Ho)、游家鑫(Jiaxin Yu)、王昱權(WANG YU-CHUAN)、(Yu-Chuan Lin)、邱翊芳(Chiu, Yi-Fang)、高敬彥(Gao, Jing-Yan)、賴姝蓉(Lai, Shu-Jung)、(Ming?Jen Chen)、黃偉謙(Huang, Wei-Chien)、田霓(Ni Tien)*、陳曄(Chen,Yeh)*,A Structural Comparison of SARS-CoV-2 Main Protease and Animal Coronaviral Main Protease Reveals Species-Specific Ligand Binding and Dimerization Mechanism,INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,2022 May,23(10):5669
SCI論文 何建宜(Chien-Yi Ho)、胡玳瑋、陳柏融(Chen, Bo-Rong)、(Chun-Chun Yang)、姚俊旭(Chun-Hsu Yao)、(Tien Ni)、(WEI-CHUAN HO)、陳悦生(Yueh-Sheng Chen)、涂智彥(Chih-Yen Tu)、張為超(Wei-Chao Chang)、吳永昌(Yang-Chang Wu)、湯智昕(Chih-Hsin Tang)、黃慧琪(Hui-Chi Huang)*、黃偉謙(Huang, Wei-Chien)*、(TZONG-SHIUN LI)*,Snail Mucus Enhances Chemosensitivity of Triple-negative Breast Cancer Via Activation of the Fas Pathway,ANTICANCER RESEARCH,2022 Feb,42(2):845-855
SCI論文 陳冠宇(Guan-Yu Chen)、潘奕澄、(Tung-Ying Wu)、(Tsung-You Yao)、王韋然(Wang, Wei-Jan)、(Wan-Jou Shen)、(Azaj Ahmed)、(Shu-Ting Chan)、湯智昕(Chih-Hsin Tang)、黃偉謙(Huang, Wei-Chien)、洪明奇(Mien-Chie Hung)、楊顓丞(Juan-Cheng Yang)*、吳永昌(Yang-Chang Wu)*,Potential natural products that target the SARS-CoV-2 spike protein identified by structure-based virtual screening, isothermal titration calorimetry and lentivirus particles pseudotyped (Vpp) infection assay,Journal of Traditional and Complementary Medicine,2022 Jan,12(1):73-89
SCI論文 江雅靖(Jiang, Ya-Jing)、(Chia-ChiaChao)、(An-Chen Chang)、陳均(Po-Chun Chen)、(Fang-Ju Chen)、(Ju-Fang Liu)、劉柏毅(LIU BO-YI)、黃章倫(Huang, Chang-Lun)、郭政宏(Jeng-Hung Guo)、黃偉謙(Huang, Wei-Chien)、湯智昕(Chih-Hsin Tang)*,Cigarette smoke-promoted increases in osteopontin expression attract mesenchymal stem cell recruitment and facilitate lung cancer metastasis,Journal of Advanced Research,2021 Dec,():
SCI論文 蘇錦宏(Su, Chin-Horng)、(Chih-Yang Lin)、蔡俊灝(Chun-Hao Tsai)、李湘萍(Hsiang-Ping Lee)、羅綸謙(Lun-Chien Lo)、黃偉謙(Huang, Wei-Chien)、吳永昌(Yang-Chang Wu)、謝慶良(Ching-Liang Hsieh)*、湯智昕(Chih-Hsin Tang)*,Betulin suppresses TNF-α and IL-1β production in osteoarthritis synovial fibroblasts by inhibiting the MEK/ERK/NF-κB pathway,Journal of Functional Foods,2021 Nov,86():104729
SCI論文 李湘萍(Hsiang-Ping Lee)、劉軒誌(Shan-Chi Liu)、王俞涵(Wang, Yu-Han)、(Bo-ChengChen)、陳賢德(Hsien-Te Chen)、李德茂(Li, Te-Mao)、黃偉謙(Huang, Wei-Chien)、許晉榮(Chin-Jung Hsu)*、吳永昌(Yang-Chang Wu)*、湯智昕(Chih-Hsin Tang)*,Cordycerebroside A suppresses VCAM-dependent monocyte adhesion in osteoarthritis synovial fibroblasts by inhibiting MEK/ERK/AP-1 signaling,Journal of Functional Foods,2021 Nov,86():104712
SCI論文 (David Achudhan)、劉軒誌(Shan-Chi Liu)、林彥佑、李湘萍(Hsiang-Ping Lee)、(Shih- Wei Wang)、黃偉謙(Huang, Wei-Chien)、吳永昌(Yang-Chang Wu)、郭悅雄(Yueh-Hsiung Kuo)*、湯智昕(Chih-Hsin Tang)*,Antcin K inhibits VEGF-dependent angiogenesis in human rheumatoid arthritis synovial fibroblasts,JOURNAL OF FOOD BIOCHEMISTRY,2021 Nov,29():e14022
SCI論文 Nguyen Thanh(Nguyen Thanh Lien Khuong)、(Jhih-Yi Chiou)、(You-Chi Liu)、鄭方茹(Cheng, Fang-Ju)、沈宜成(Yi-Cheng Shen)、陳朝榮(Chao-Jung Chen)、湯智昕(Chih-Hsin Tang)、黃偉謙(Huang, Wei-Chien)*、陳家弘(Chia-Hung Chen)*、涂智彥(Chih-Yen Tu)*,l-lactic acidosis confers insensitivity to PKC inhibitors by competing for uptake via monocarboxylate transporters,JOURNAL OF CELLULAR PHYSIOLOGY,2021 Sep,():1-15
SCI論文 沈宜成(Yi-Cheng Shen)、夏寧憶(Ning-Yi Hsia)*、吳婉華(Wan-Hua Wu)、林橙莉(Cheng-Li Lin)、沈德群(Shen, Te-Chun)*、黃偉謙(Huang, Wei-Chien)*,Age‑related macular degeneration and premorbid allergic diseases: a population‑based case–control study,Scientific Reports,2021 Aug,11():16537-16537
SCI論文 鄭方茹(Cheng, Fang-Ju)、(Thanh Kieu Huynh)、(Chia-Shin Yang)、胡玳瑋、沈宜成(Yi-Cheng Shen)、涂智彥(Chih-Yen Tu)、吳永昌(Yang-Chang Wu)、湯智昕(Chih-Hsin Tang)、黃偉謙(Huang, Wei-Chien)*、陳曄(Chen,Yeh)*、何建宜(Chien-Yi Ho)*,Hesperidin is a Potential Inhibitor against SARS-CoV-2 Infection,Nutrients,2021 Aug,13(8):2800
SCI論文 (Thanh Kieu Huynh)、黃至豪(Huang ChihHao)、陳貞妤、姚京含(Yao, Jing-Han)、(Yi-Shiang Yang)、魏雅鈴(Ya-Ling Wei)、陳筱凡(Chen Hsiao-Fan)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、徐媛曼(Yuan-Man Hsu)、劉良智(Liang-Chih Liu)*、黃偉謙(Huang, Wei-Chien)*,miR-221 confers lapatinib resistance by negatively regulating p27kip1 in HER2-positive breast cancer,CANCER SCIENCE,2021 Aug,112():4234-4245
SCI論文 陳家弘(Chia-Hung Chen)、王柏幃(Wang, Bo-Wei)、蕭宇君(Hsiao, Yu-Chun)、(Chun-Yi Wu)、鄭方茹(Cheng, Fang-Ju)、夏德椿(Te-Chun Hsia)、(Chih-Yi Chen)、(Yihua Wang)、(Zhang Weihua)、鄒瑞煌(Ruey-Hwang Chou)、湯智昕(Chih-Hsin Tang)、(Yun-Ju Chen)、魏雅鈴(Ya-Ling Wei)、(Jennifer L. Hsu)、涂智彥(Chih-Yen Tu)*、洪明奇(Mien-Chie Hung)*、黃偉謙(Huang, Wei-Chien)*,PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs,ONCOGENE,2021 Jul,0():
SCI論文 何宥豪(He, Yu-Hao)、葉名焮、陳筱凡(Chen Hsiao-Fan)、(Wang T.-S)、(Wong R.-H)、魏雅鈴(Ya-Ling Wei)、Huynh Kieu T(Huynh Kieu Thanh)、胡玳瑋、鄭方茹(Cheng, Fang-Ju)、陳貞妤、胡書瑋(Hu, Shu-Wei)、(Huang C.-C.)、陳曄(Chen,Yeh)、游家鑫(Jiaxin Yu)、鄭維中(Cheng, Wei-Chung)、(Shen P.-C)、劉良智(Liang-Chih Liu)、黃至豪(Huang ChihHao)、(Chang Y.-J)、黃偉謙(Huang, Wei-Chien)*,ERα determines the chemo-resistant function of mutant p53 involving the switch between lincRNA-p21 and DDB2 expressions,Molecular Therapy-Nucleic Acids,2021 Jul,25():536-553
SCI論文 王柏幃(Wang, Bo-Wei)、黃至豪(Huang ChihHao)、劉良智(Liang-Chih Liu)、鄭方茹(Cheng, Fang-Ju)、魏雅鈴(Ya-Ling Wei)、(Yueh-Ming Lin)、(Yu-Fei Wang)、(Ching-Ting Wei)、陳曄(Chen,Yeh)*、(Yun-Ju Chen)*、黃偉謙(Huang, Wei-Chien)*,Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2,Frontiers in Pharmacology,2021 Jun,12():614673.
SCI論文 吳佳燕、(Chien YC)、(Tsai IC)、(Hung CC)、黃偉謙(Huang, Wei-Chien)、劉良智(Liang-Chih Liu)*、余永倫(Yung-Luen Yu)*,Capsanthin induces G1/S phase arrest, erlotinib-sensitivity and inhibits tumor progression by suppressing EZH2-mediated epigenetically silencing of p21 in triple-negative breast cancer cells,Aging-US,2021 May,13(9):12514-12525
SCI論文 陳曄(Chen,Yeh)、黃偉謙(Wei-Chien Huang)、(Chia-Shin Yang)、鄭方茹(Cheng, Fang-Ju)、(Yi-Fang Chiu)、陳筱凡(Chen Hsiao-Fan)、(Thanh Kieu Huynh)、(Chih-Feng Huang)、陳家弘(Chia-Hung Chen)、王雪君(Wang, Hsueh-Chun)、洪明奇(Mien-Chie Hung)*,Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment,American Journal of Cancer Research,2021 Mar,11(3):827-836
SCI論文 戴昀皓(Dai,Yun-Hao)、陳冠宇(Guan-Yu Chen)、湯智昕(Chih-Hsin Tang)、黃偉謙(Wei-Chien Huang)、楊顓丞(Juan-Cheng Yang)*、吳永昌(Yang-Chang Wu)*,Drug Screening of Potential Multiple Target Inhibitors for Estrogen Receptor-α-positive Breast Cancer,IN VIVO,2021 Mar,35(2):761-777
SCI論文 鄭方茹(Cheng, Fang-Ju)、陳家弘(Chia-Hung Chen)、蔡文正(Tsai, Wen-Chen)、王柏幃(Wang, Bo-Wei)、游孟潔(Meng-Chieh Yu)、夏德椿(Te-Chun Hsia)、魏雅鈴(Ya-Ling Wei)、蕭宇君(Hsiao, Yu-Chun)、胡玳瑋、何建宜(Chien-Yi Ho)、(Tzong-Shiun Li)、(Chun-Yi Wu)、(Wen-Yu Chou)、余永倫(Yung-Luen Yu)、湯智昕(Chih-Hsin Tang)、(Chih-Yi Chen)、(Chuan-Mu Chen)、(Jennifer L. Hsu)、(Hsiao-Fan Chen)、陳曄(Chen,Yeh)、涂智彥(Chih-Yen Tu)*、洪明奇(Mien-Chie Hung)*、黃偉謙(Wei-Chien Huang)*,Cigarette Smoke-induced LKB1/AMPK Pathway Deficiency Reduces EGFR TKI Sensitivity in NSCLC,ONCOGENE,2021 Feb,40(6):1162-1175
SCI論文 (Po-I Liu)、(An-Chen Chang)、(Jiun-Lin Lai)、(Tien-Huang Lin)、蔡俊灝(Chun-Hao Tsai)、(Po-Chun Chen)、江雅靖(Jiang, Ya-Jing)、林良蔚(Lin, Liang-Wei)、黃偉謙(Wei-Chien Huang)、(Shun-Fa Yang)*、湯智昕(Chih-Hsin Tang)*,Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases,ONCOGENE,2021 Jan,():
SCI論文 楊佳昕(Yang, Chia-Shin)、黃偉謙(Wei-Chien Huang)、柯子平(Tzu-Ping Ko)、王昱權(WANG YU-CHUAN)、王惠鈞(Andrew H.-J. Wang)、陳曄(Chen,Yeh)*,Crystal structure of the N-terminal domain of TagH reveals a potential drug targeting site,BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,2021 Jan,15(536):1-6
SCI論文 李湘萍(Hsiang-Ping Lee)、吳永昌(Yang-Chang Wu)、(Bo-Cheng Chen)、劉軒誌(Shan-Chi Liu)、李德茂(Li, Te-Mao)、黃偉謙(Wei-Chien Huang)、許晉榮(Chin-Jung Hsu)、湯智昕(Chih-Hsin Tang)*,Soya-cerebroside reduces interleukin production in human rheumatoid arthritis synovial fibroblasts by inhibiting the ERK, NF-κB and AP-1 signalling pathways,FOOD AND AGRICULTURAL IMMUNOLOGY,2020 Jan,31(1):740-750
SCI論文 陳冠良(Chen, Guang-Liang)、(SHOU-CHENG WANG)、黃偉謙(Wei-Chien Huang)、張文馨(Wen-Shin Chang)、蔡佳紋(Chia-Wen, Tsai)、李欣庭(Li, Hsin-Ting)、沈德群(Te-Chun Shen)、夏德椿(Te-Chun Hsia)、包大靝(Da-Tian Bau)*,The Association of MMP-11 Promoter Polymorphisms with Susceptibility to Lung Cancer in Taiwan,ANTICANCER RESEARCH,2019 Oct,39(10):5375-5380
SCI論文 (Bo-Yin Yang)、(Chung-Hsuan Hu)、黃偉謙(Wei-Chien Huang)、何建宜(Chien-Yi Ho)、姚俊旭(Chun-Hsu Yao)*、(Chiung-Hua Huang)*,Effects of Bilayer Nanofibrous Scaffolds Containing Curcumin/Lithospermum Radix Extract on Wound Healing in Streptozotocin-Induced Diabetic Rats,Polymers,2019 Oct,11(11):
SCI論文 (Thanh Kieu Huynh)、何建宜(Chien-Yi Ho)、蔡奇樺(Chi-Hua Tsai)、(Chien-Kuo Wang)、陳韻如(Yun-Ju Chen)、包大靝(Da-Tian Bau)、涂智彥(Chih-Yen Tu)、(Tzong-Shiun Li)*、黃偉謙(Wei-Chien Huang)*,Proteasome Inhibitors Suppress ErbB Family Expression Through HSP90-Mediated Lysosomal Degradation,INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,2019 Sep,2019(20):1-15
SCI論文 (Huiquan Liu)、(Ayse Ertay)、(Ping Peng)、(Juanjuan Li)、(Dian Liu)、(Hua Xiong)、(Yanmei Zou)、(Hong Qiu)、(David Hancock)、(Xianglin Yuan)、黃偉謙(Wei-Chien Huang)、(Rob M Ewing)、(Julian Downward)、(Yihua Wang)*,SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity,Molecular Oncology,2019 Sep,13(9):1874-1886
SCI論文 (Maofeng Wang)、(Chia-Chia Chao)、(Po-Chun Chen)、(Po-I. Liu)、(Yi-Chen Yang)、蘇振銘(Su, Chen-Ming)、黃偉謙(Wei-Chien Huang)、湯智昕(Chih-Hsin Tang)*,Thrombospondin enhances RANKL-dependent osteoclastogenesis and facilitates lung cancer bone metastasis,BIOCHEMICAL PHARMACOLOGY,2019 Aug,166(2019):23-32
SCI論文 (Yi Chen Yang)、(Pei Chen Chiou)、(Po Chun Chen)、(Po Yi Liu)、黃偉謙(Wei-Chien Huang)、(Chia Chia Chao)、湯智昕(Chih-Hsin Tang)*,Melatonin reduces lung cancer stemness through inhibiting of PLC, ERK, p38, β-catenin, and Twist pathways,ENVIRONMENTAL TOXICOLOGY,2019 Feb,34(2):203-209
SCI論文 陳貞妤(Jhen-Yu Chen)、黃偉謙(Wei-Chien Huang)、(Ching-Ting Wei)、(Pei-Hsuan Chien)、陳韻如(Yun-Ju Chen)*,The C-Terminus of Hepatitis B Virus-encoded X Protein Is Required for Lapatinib Sensitivity in Hepatocellular Carcinoma Cells,ANTICANCER RESEARCH,2019 Feb,39(2):721-726
SCI論文 涂智彥(Chih-Yen Tu)、王柏幃(Wang, Bo-Wei)、(Chuan-Mu Chen)、鄭方茹(Cheng, Fang-Ju)、陳家弘(Chia-Hung Chen)、夏德椿(Te-Chun Hsia)、魏雅鈴(Ya-Ling Wei)、(Chih-Yi Chen)、謝宜珊(I-Shan Hsieh)、葉屹倫(Yeh, Yi-Lun)、王立昀(Wang, Li-Yun)、張為超(Wei-Chao Chang)*、黃偉謙(Wei-Chien Huang)*,Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression,American Journal of Cancer Research,2018 Dec,8(12):2575-2589
SCI論文 李培志(Lee, Pei-Chih)、(Yueh-Fu Fang)、(Hirohito Yamaguchi)、王韋然(Wang, Wei-Jan)、(Tse-Ching Chen)、(Xuan Hong)、(Baozhen Ke)、(Weiya Xia)、(Yongkun Wei)、(Zhengyu Zha)、(Yan Wang)、(Han-Pin Kuo)、(Chih-Wei Wang)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)、黃偉謙(Wei-Chien Huang)、(Shu-Fen Chiang)、(Lei Nie)、(Junwei Hou)、(Chun-Te Chen)、(Longfei Huo)、楊文豪(Yang,Wen-Hao)、(Rong Deng)、(Katsuya Nakai)、(Yi-Hsin Hsu)、(Shih-Shin Chang)、(Tai-Jan Chiu)、(Jun Tang)、(Ran Zhang)、(Li Wang)、(Bingliang Fang)、(Ting Chen)、(Kwok-Kin Wong)、(Jennifer L. Hsu)、洪明奇*,Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer,CANCER CELL,2018 Dec,34(6):954-969
SCI論文 涂智彥(Tu, Chih-Yen)、鄭方茹(Cheng, Fang-Ju)*、(Chuan-Mu Chen)*、(Shu-Ling Wang)*、(Yu-Chun Hsiao)、陳家弘(Chen, Chia-Hung)、夏德椿(Hsia, Te-Chun)、何宥豪(He, Yu-Hao)、王柏幃、謝宜珊(Hsieh, I-Shan)、葉屹倫(Yeh, Yi-Lun)、(Chih-Hsin Tang)、(Yun-Ju Chen)、黃偉謙(Huang, Wei-Chien)*,Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs,Molecular Oncology,2018 May,12(5):705-723
SCI論文 (Changwei Dou)、(Zhikui Liu)、(Kangsheng Tu)、(Hongbin Zhang)、(Chen Chen)、(Usman Yaqoob)、(Yuanguo Wang)、(Jialing Wen)、(Jan van Deursen)、(Delphine Sicard)、(Daniel Tschumperlin)、(Hongzhi Zou)、黃偉謙(Huang, Wei-Chien)、(Raul Urrutia)、(Vijay H. Shah)、(Ningling Kang)*,P300 Acetyltransferase Mediates Stiffness-Induced Activation of Hepatic Stellate Cells Into Tumor-promoting Myofibroblasts,Gastroenterology,2018 Feb,S0016-5085(18):30209-9
SCI論文 (Jia-Chen Tung)、黃偉謙(Huang, Wei-Chien)、楊顓丞、陳冠宇(Guan-Yu Chen)、范紀鎮(Chi-Chen Fan)、簡毓娟(Chuan , Chien-Yu)、林佩姍、龍世俊(Shih-Chun Candice Lung)*、張為超(Chang, Wei-Chao)*,Auramine O, an incense smoke ingredient, promotes lung cancer malignancy,ENVIRONMENTAL TOXICOLOGY,2017 Nov,32(11):2379-2391
SCI論文 陳家弘(Chen, Chia-Hung)、夏德椿(Hsia, Te-Chun)、葉名焮(Yeh, Ming-Hsin)、陳宗偉(Tsung-Wei Chen)、陳韻如(Chen, Yun-Ju)、(Chen, Jung-Tsu)、魏雅鈴(Ya-Ling Wei)、涂智彥(Tu, Chih-Yen)*、黃偉謙(Huang, Wei-Chien)*,MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701,Molecular Oncology,2017 Sep,11(9):1273-1281
SCI論文 (Wen-Ling Wang)、黃偉謙(Wei-Chien Huang)*,Rac1 is a potential target to circumvent radioresistance (WOS收錄文件類型:Editorial Material),Journal of Thoracic Disease,2016 Nov,8(11):E1475-E1477
SCI論文 黃偉謙(Wei-Chien Huang)、(Chao-Ming Hung)、(Ching-Ting Wei)、(Tsung-Ming Chen)、(Pei-Hsuan Chien)、(Hsiao-Lin Pan)、(Yueh-Ming Lin)、陳韻如(Chen Yun-Ju)*,Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells,Oncotarget,2016 Sep,7(38):62352-62363
SCI論文 陳雯淑(Wen-Shu Chen)、劉良智(Liu, Liang-Chih)、顏家瑞(Chia-Jui Yen)、陳韻如(Yun-Ju Chen)、陳貞妤(Chen, Jhen-Yu)、何建宜(Chien-Yi Ho)、劉淑惠(Liu, Shu-Hui)、陳青周(Ching-Chow Chen)、黃偉謙(Wei-Chien Huang)*,Nuclear IKKα mediates microRNA-7/-103/107/21 inductions to downregualte maspin expression in response to HBx overexpression,Oncotarget,2016 Jul,():1-15
SCI論文 張玲菊(Ling-Chu Chang)*、余永倫(Yung-Luen Yu)、謝閔凔(Min-Tsang Hsieh)、(Sheng-Hung Wang)、鄒瑞煌(Ruey-Hwang Chou)、黃偉謙(Wei-Chien Huang)、(Hui-Yi Lin)、(Hsin-Yi Hung)、郭盛助(Li-Jiau Huang),A novel microtubule inhibitor, MT3-037, causes cancer cell apoptosis by inducing mitotic arrest and interfering with microtubule dynamics,American Journal of Cancer Research,2016 Jun,6(4):747-763
SCI論文 陳貞妤(Chen, Jhen-Yu)、陳韻如(Yun-Ju Chen)、顏家瑞(Chia-Jui Yen)、陳雯淑(Wen-Shu Chen)、黃偉謙(Wei-Chien Huang)*,HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3,Oncotarget,2016 Jan,7(1):473-489
SCI論文 (Yu-Jun Hsiao)、(Ming-Hsin Yeh)、Yun-Ju Chen、Ju fang Liu、湯智昕(Tang Chih-Hsin)、黃偉謙(Wei-Chien Huang)*,Lapatinib increases motility of triple-negative breast cancer cells by decreasing MiRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6,Oncotarget,2015 Sep,():
SCI論文 (Wen-Bin Wu)*、黃偉謙(Wei-Chien Huang),Therapeutic Strategies against Inflammation-Related Diseases: Molecular Mechanisms and Clinical Applications (文章性質:Editorial),Biomed Research International,2015 Aug,2015():382730-382730
SCI論文 (Wen-Shu Chen)、(Chia-Jui Yen)、(Yun-Ju Chen)、(Jhen-Yu Chen)、(Li-Yun Wang)、(Shu-Jun Chiu)、(Wen-Ling Shih)、何建宜(Chien-Yi Ho)、(Tzu-Tang Wei)、(Hsiao-Lin Pan)、(Pei-Hsuan Chien)、(Ching-Chow Chen)*、洪明奇(Mien-Chie Hung)*、黃偉謙(Wei-Chien Huang)*,MiRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin.,Oncotarget,2015 Jul,():
SCI論文 (Wu CS)、(Lee TY)、鄒瑞煌(Ruey-Hwang Chou)、(Yen CJ)、黃偉謙(Wei-Chien Huang)、(Wu CY)、余永倫(Yung-Luen Yu)*,Development of a Highly Sensitive Glycan Microarray for Quantifying AFP-L3 for Early Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma,PLoS One,2014 Jun,9(6):e99959-e99959
SCI論文 吳承修、(Yen CJ)、鄒瑞煌(Ruey-Hwang Chou)、陳佳妮、黃偉謙(Wei-Chien Huang)、(Wu CY)、余永倫(Yung-Luen Yu)*,Downregulation of microRNA-15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2–induced Globo H expression,INTERNATIONAL JOURNAL OF CANCER,2014 Apr,134(7):1638-1647
SCI論文 (Chao-Ming Hung)、黃偉謙(Wei-Chien Huang)、(Hsiao-Lin Pan)、(Pei-Hsuan Chien)、(Chih-Wen Lin)、(Lei-Chin Chen)、(Yu-Fong Chien)、(Ching-Chiao Lin)、(Kar-Hee Leow)、(Wen-Shu Chen)、(Jhen-Yu Chen)、(Pao-Sheng Hou)、何建宜(Chien-Yi Ho)、(Yun-Ju Chen)*,Hepatitis B virus X up-regulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells,JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY,2014 Jan,():
SCI論文 涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)、夏德椿(Te-Chun Hsia)、(Min-Hsiang Hsu)、魏雅鈴(Ya-Ling Wei)、(Meng-Chie Yu)、(Wen-Shu Chen)、(Ke-Wei Hsu)、(Ming-Hsin Yeh)、劉良智(Liang-Chih Liu)、(Yun-Ju Chen)*、黃偉謙(Wei-Chien Huang)*,Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells,Biomed Research International,2014 Jan,2014():
SCI論文 黃偉謙(Wei-Chien Huang)、(Yi-Ling Hsieh)、(Chao-Ming Hung)、(Pei-Hsuan Chien)、(Yu-Fong Chien)、(Lei-Chin Chen)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)、(Sheng-Chieh Hsu)、(Yueh-Ming Lin)、(Yun- Ju Chen)*,BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib,PLoS One,2013 Dec,8(12):e83627-e83627
SCI論文 (Yun-Ju Chen)、葉名焮(Ming-Hsin, Alex, Yeh)、游孟潔(Meng-Chieh Yu)、魏雅鈴(Ya-Ling Wei)、(Wen-Shu Chen)、(Jhen-Yu Chen)、(Chih-Yu Shih)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)、夏德椿(Te-Chun Hsia)、(Pei-Hsuan Chien)、(Shu-Hui Liu)、余永倫(Yung-Luen Yu)、黃偉謙(Wei-Chien Huang)*,Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors,BREAST CANCER RESEARCH,2013 Nov,15(6):R108-R108
SCI論文 (Jiangong Ren)、(Lakshmi R. Bollu)、(Fei Su)、(Guang Gao)、(Lei Xu)、黃偉謙(Wei-Chien Huang)、洪明奇(Mien-Chie Hung)、(Zhang Weihua)*,EGFR/SGLTI Interaction Does Not Respond to EGFR Modulators, But Inhibition of SGLT1 Sensitizes Prostate Cancer Cells to EGFR Tyrosine Kinase Inhibitors,PROSTATE,2013 Sep,73(13):1453-1461
SCI論文 黃宗祺(Tzungchi Huang)、(Tung-Hsin Wu)、(Yang-Hsin Lin)、(Wan-Yuo Guo)、黃偉謙(Wei-Chien Huang)、(Chung-Jung Lin)*,Quantitative Flow Measurement by Digital Subtraction Angiography in Cerebral Carotid Stenosis Using Optical Flow Method,Journal of X-Ray Science and Technology,2013 May,0():
SCI論文 (Yun-Ju Chen)、(Pei-Hsuan Chien)、陳雯淑(Wen-Shu Chen)、(Yu-Fong Chien)、(Ya-Ying Hsu)、(Li-Yun Wang)、陳貞妤(Jhen-Yu Chen)、(Chih-Wen Lin)、黃宗祺(Tzungchi Huang)、余永倫(Yung-Luen Yu)、黃偉謙(Wei-Chien Huang)*,Hepatitis B virus-encoded X protein down-regulates EGFR expression via inducing microRNA-7 in hepatocellular carcinoma cells.,Evidence-based Complementary and Alternative Medicine,2013 May,2013(682380):1-10
SCI論文 黃偉謙(Wei-Chien Huang)*、(Sheng-Chie Hsu)、(Shyh-Jer Huang)、(Yun-Ju Chen)、(Yu-Chun Hsiao)、(Weihua Zhang)、(Isaiah J Fidler)、洪明奇(Mien-Chie Hung)*,Exogenous expression of human SGLT1 exhibits aggregations in sodium dodecyl sulfate polyacrylamide gel electrophoresis,American Journal of Translational Research,2013 May,5(4):441-449
SCI論文 余永倫(Yung-Luen Yu)*、鄒瑞煌(Ruey-Hwang Chou)、梁嘉紘(Jia-Hong Liang)、張維容(Wei-Jung Chang)、蘇國榮(Kuo-Jung Su)、曾嬿儒(Yen-Ju Tseng)、黃偉謙(Wei-Chien Huang)、王紹椿(Shao-Chun Wang)、洪明奇(Mien-Chie Hung)*,Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides,PLoS One,2013 Apr,8(4):e61362-1
SCI論文 王耀慶(Yao-Ching Wang)、曾勛琳、林仰賢、高嘉鴻(Chia-Hung Kao)、黃偉謙(Wei-Chien Huang)、黃宗祺(Tzungchi Huang)*,Improvement of internal tumor volumes of non-small cell lung cancer patients for radiation treatment planning using interpolated average CT in PET/CT,PLoS One,2013 Apr,0():
SCI論文 夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、(Yun-Ju Chen)、魏雅鈴(Ya-Ling Wei)、(Meng-Chieh Yu)、(Sheng-Chie Hsu)、(Shing-Ling Tsai)、(Wen-Shu Chen)、葉名焮(Ming-Hsin, Alex, Yeh)、(Chia-Jui Yen)、余永倫(Yung-Luen Yu)、黃宗祺(Tzungchi Huang)、黃志揚(Chih-Yang Huang)、洪明奇(Mien-Chie Hung)、黃偉謙(Wei-Chien Huang)*,Lapatinib-mediated COX-2 expression via EGFR/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells,MOLECULAR PHARMACOLOGY,2013 ,20(3):2-13
SCI論文 黃偉謙(Wei-Chien Huang)*、洪明奇(Mien-Chie Hung)*,Beyond NF-κB activation: nuclear functions of IκB kinase α,JOURNAL OF BIOMEDICAL SCIENCE,2013 ,20(1):3
SCI論文 (Lisheng Zhang)、(Lixin Yang)、(Xiyong Liu)、(Wei Chen)、(Lufen Chang)、(Linling Chen)、(Sofia Loera)、(Peiguo Chu)、黃偉謙(Wei-Chien Huang)、(Yun-Ru Liu)、(Yun Yen)*,MiR-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through NF-κB pathways.,HEPATOLOGY,2012 Dec,():
SCI論文 蔡士彰(Shih-Chang Tsai)、黃雯雯(Wenwen Huang)、黃偉謙(Wei-Chien Huang)、呂啟誠(Chi-Cheng Lu)、江若華(Jo-Hua Chiang)、彭淑芬(Shu-Fen Peng)、鍾景光(Jing-Gung Chung)、林宥欣(Yu-Hsin. Lin)、徐媛曼(Yuan-Man Hsu)、雨谷榮(Sakae Amagaya)、楊家欣(Yang Jai-Sing)*,ERK-modulated intrinsic signaling and G2/M phase arrest contribute to the induction of apoptotic death by allyl isothiocyanate in MDA-MB-468 human breast adenocarcinoma cells,INTERNATIONAL JOURNAL OF ONCOLOGY,2012 Dec,41(6):2065-2072
Other論文 (Blessing A)、Xu L、(Gao G)、(Bollu LR)、(Ren J)、(Li H)、(Wu X)、(Su F)、黃偉謙(Wei-Chien Huang)、洪明奇(Mien-Chie Hung)、(Huo L)、(Palapattu GS)、(Weihua Z)*,Sodium/Glucose Co-transporter 1 Expression Increases in human diseased prostate,Journal of Cancer Science & Therapy,2012 Aug,4(9):306-312
SCI論文 (Chen-Shiou Wu)、(Chia-Jui Yen)、鄒瑞煌(Ruey-Hwang Chou)、(Shiou-Ting Li)、黃偉謙(Wei-Chien Huang)、(Chien-Tai Ren)、(Chung-Yi Wu)*、余永倫(Yung-Luen Yu)*,Cancer-associated carbohydrate antigens as potential biomarkers for hepatocellular carcinoma,PLoS One,2012 Jul,7(7):e39466-e39466
SCI論文 顏家瑞(Chia-Jui Yen)、(Yih-Jyh Lin)、(Chia-Sheng Yen)、(Hung-Wen Tsai,)、(Ting-Fen Tsai)、(Kwang-Yu Chang)、黃偉謙(Wei-Chien Huang)、(Pin-Wen Lin)、(Chi-Wu Chiang)、(Ting-Tsung Chang)*,Hepatitis B Virus X Protein Upregulates mTOR Signaling through IKKβ to Increase Cell Proliferation and VEGF Production in Hepatocellular Carcinoma,PLoS One,2012 Jul,7(7):e41931-e4193
SCI論文 黃偉謙(Wei-Chien Huang)*、陳雯淑(Wen-Shu Chen)、陳韻如(Yun-Ju Chen)、王利芸(Li-Yun Wang)、許勝捷(Sheng-Chieh Hsu)、陳青周(Ching-Chow Chen)、洪明奇(Mien-Chie Hung),Hepatitis B Virus X Protein Induces IKKα Nuclear Translocation via Akt-dependent Phosphorylation to Promote The Motility of Hepatocarcinoma Cells,JOURNAL OF CELLULAR PHYSIOLOGY,2012 Apr,227(4):1446-1454
Other論文 黃偉謙(Wei-Chien Huang)*、(Chen, Y-J.)、洪明奇(Mien-Chie Hung)*,Implication of nuclear EGFR in the development of resistance to anticancer therapies,BioMedicine,2011 Dec,1(1):2-10
SCI論文 黃偉謙(Wei-Chien Huang)*、陳韻如(Yun-Ju Chen)、李龍緣(Long-Yuan Li)、魏雅鈴(Ya-Ling Wei)、許勝捷(Sheng-Chieh Hsu)、(Shing-Ling Tsai)、(Pei-Chun Chiu)、(Wei-Pang Huang)、(Ying-Nai Wang)、(Chung-Hsuan Chen)、張為超(Wei-Chao Chang)、(Wen-Chang Chang)、(Andy Jer-En Chen)、蔡長海(Chang-Hai Tsai)、洪明奇(Mien-Chie Hung)*,Nuclear translocation of EGFR by AKT-dependent phosphorylation enhances BCRP/ABCG2 expression in gefitinib-resistant cells,JOURNAL OF BIOLOGICAL CHEMISTRY,2011 Jun,286(23):20558-20568
SCI論文 (Chia-Wei Chou)、(Ming-Shiang Wu)、黃偉謙(Wei-Chien Huang)、(Ching-Chow Chen)*,HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells,PLoS One,2011 Mar,6(3):e18087-e18087
SCI論文 陳韻如(Yun-Ju Chen)、黃偉謙(Wei-Chien Huang)*、魏雅鈴(Ya-Ling Wei)、許勝捷(Sheng-Chieh Hsu)、(Ping Yuan)、(Heather Y. Lin)、(Ignacio I. Wistuba)、(J. Jack Lee)、(Chia-Jui Yen)、(Wu-Chou Su)、(Kwang-Yu Chang)、(Wen-Chang Chang)、(Tse-Chuan Chou)、(Chao-Kai Chou)、蔡長海(Chang-Hai Tsai)、洪明奇(Mien-Chie Hung)*,Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-type EGFR-expressing Cells,PLoS One,2011 ,():
SCI論文 黃偉謙(Wei-Chien Huang)、(Yang PM)、(Lin Yi-Chu)、(Wen-Yu Huang)、(Hui-Ann Wu)、(Wei-Lun Chen)、(Yu-Fan Chang)、(Chia-Wei Chou)、(Cherng-Chyi Tzeng)、(Yeh-Long Chen)、(Ching-Chow Chen)*,Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis.,JOURNAL OF CELLULAR AND MOLECULAR MEDICINE,2010 Mar,14(3):687-698
SCI論文 黃偉謙(Wei-Chien Huang)*、洪明奇(Mien-Chie Hung)*,Induction of Akt activity by chemotherapy confers acquired resistance,JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,2009 Mar,108(3):180-194
SCI論文 (Chao-Kai Chou)、(Dung-Fang Lee)、(Hui-Lung Sun)、李龍緣(Long-Yuan Li)、林俊毅(Chun-Yi Lin)、黃偉謙(Wei-Chien Huang)、(Jung-Mao Hsu)、(Hsu-Ping Kuo)、(Hirohito Yamaguchi)、(Ying-Nai Wang)、(Mo Liu)、(Hsin-Yi Wu)、(Pao-Chi Liao)、(Chia-Jui Yen)、洪明奇(Mien-Chie Hung)*,The suppression of MAD1 by AKT-mediated phosphorylation activates MAD1 target genes transcription,MOLECULAR CARCINOGENESIS,2009 ,():
SCI論文 (Weihua Zhang)、(Rachel Tsan)、黃偉謙(Wei-Chien Huang)、(Qiuyu Wu)、(Chao-Hua Chiu)、(Isaiah J. Fidler)*、洪明奇(Mien-Chie Hung)*,Survival of Cancer Cells is Maintained by EGFR Activity,CANCER CELL,2008 May,13(5):385-393
SCI論文 楊哲彥(Yang, Jer-Yen)、(Cong S. Zong)、(Weiya Xia)、(Hirohito Yamaguchi)、(Qingqing Ding)、(Xiaoming Xie)、(Jing-Yu Lang)、賴建成(Chien-Chen Lai)、張君如(Chang Chun Ju)、黃偉謙(Wei-Chien Huang)、(Hsin Huang)、(Hsu-Ping Kuo)、(Dung-Fang Lee)、李龍緣(Long-Yuan Li)、(Huang-Chun Lien)、(Xiaoyun Cheng)、(King-Jen Chang)、(Chwan-Deng Hsiao)、蔡輔仁(Fuu-Jen Tsai)、蔡長海(Chang-Hai Tsai)、(Aysegul A. Sahin)、(William J. Muller)、(Gordon B. Mills)、(Dihua Yu)、(Gabriel N. Hortobagyi)、洪明奇(Mien-Chie Hung)*,ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation,NATURE CELL BIOLOGY,2008 Feb,10(2):138-148
SCI論文 (Dung-Fang Lee)、(Hsu-Ping Kuo)、(Chun-Te Chen)、(Jung-Mao Hsu)、(Chao-Kai Chou)、(Yongkun Wei)、(Hui-Lung Sun)、李龍緣(Long-Yuan Li)、(Bo Ping)、黃偉謙(Wei-Chien Huang)、(Xianghuo He)、(Jen-Yu Hung)、(Chien-Chen Lai)、(Qinqing Ding)、蘇振良(Jen-Liang Su)、楊哲彥(Yang, Jer-Yen)、(Aysegul A. Sahin)、(Gabriel N. Hortobagyi)、蔡輔仁(Fuu-Jen Tsai)、蔡長海(Chang-Hai Tsai)、洪明奇*,IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway,CELL,2007 Aug,130(3):440-455
SCI論文 黃偉謙(Wei-Chien Huang)、(Tsai-Kai Ju)、洪明奇*、(Ching-Chow Chen)*,Phosphorylation of CBP by IKKa Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-kB,Molecular Cell,2007 Apr,26(1):75-87
SCI論文 (Jun-Jie Chen)、黃偉謙(Wei-Chien Huang)、(Ching-Chow Chen)*,Transcriptional regulation of cyclooxygenase-2 by proteasome inhibitor MG132 involves CRE element binding CCAAT/enhancer binding protein delta and recruitment of CBP.,MOLECULAR BIOLOGY OF THE CELL,2005 Dec,16(16):5579-5591
SCI論文 黃偉謙(Wei-Chien Huang)、(Ching-Chow Chen)*,Akt Phosphorylation of p300 at Ser-1834 Is Essential for Its Histone Acetyltransferase and Transcriptional Activity.,MOLECULAR AND CELLULAR BIOLOGY,2005 Aug,25(15):6592-6602
SCI論文 蔡金川*、賴東淵、黃偉謙(Wei-Chien Huang)、(I-Min Liu)、(Shorong-Shii Liou),Role of cGMP signals in tetramethylpyrazine induced relaxation of the isolated rat aortic strip,LIFE SCIENCES,2005 Jan,(77):1416-1424
SCI論文 黃偉謙(Wei-Chien Huang)、(Su-Tin Chan)、(Tzu-Lin Yang)、(Chern-Chy Tzeng)、(Ching-Chow Chen)*,Inhibition of ICAM-1 gene expression, monocyte adhesion, and cancer cell invasion by targeting IKK complex: molecular and functional study of novel alpha-methylene-gamma-butyrolactone derivatives,CARCINOGENESIS,2004 Oct,25(10):1925-1934
SCI論文 (Ching-Chow Chen)、(Man-Ping Chow)、黃偉謙(Wei-Chien Huang)、(Yi-Chu Lin)、(Ya-Jen Chang),Flavonoids Inhibit TNF-alpha-induced Up-regulation of ICAM-1 in Respiratory Epithelial Cells through AP-1 and NF-kB: Structure-activity Relationships,MOLECULAR PHARMACOLOGY,2004 Sep,66(3):683-693
SCI論文 黃偉謙(Wei-Chien Huang)、(Jun-Jie Chen)、(Hiroyasu Inoue)、(Ching-Chow Chen)*,Tyrosine phosphorylation of IKKa/b by PKC-dependent c-Src activation is involved in TNF-α-induced COX-2 expression,JOURNAL OF IMMUNOLOGY,2003 May,170(9):4767-4775
SCI論文 黃偉謙(Wei-Chien Huang)、(Jun-Jie Chen)、(Ching-Chow Chen)*,c-Src-dependent tyrosine phosphorylation of IKKβ is involved in TNF-α-induced ICAM-1 expression.,JOURNAL OF BIOLOGICAL CHEMISTRY,2003 Mar,278(11):9944-9952
 
研討會論文/Conference Papers
(發表主題或論文名稱,研討會名稱,演講地點,研討會期間,受邀演講題目)
1﹒ Identification of UBE2T as a Potential Therapeutic Target in Triple-Negative Breast Cancer,第27屆台灣癌症聯合學術年會,台大醫院國際會議中心,2023.5.6 ~ 2023.5.7,
2﹒ The Correlation Between MRI T2* Values and the Status of Red Blood Cells With Oxygen,第27屆台灣癌症聯合學術年會,台大醫院國際會議中心,2023.5.6 ~ 2023.5.7,
3﹒ DW-MRI Measurement for Monitoring 3D Tumor Cell Culture,第27屆台灣癌症聯合學術年會,台大醫院國際會議中心,2023.5.6 ~ 2023.5.7,
4﹒ Cigarette smoke promotes proliferation of non-small cell lung cancer (NSCLC) via enhancing glucose uptake and glycolysis.,ELCC 2018 European Lung Cancer Congress,Geneva, Switzerland,2018.4.11 ~ 2018.4.14,
5﹒ Snail mucus induces extrinsic apoptosis in melanoma,Perspectives on skin cancer prevention,Les Diablerets, Switzerland,2018.4.8 ~ 2018.4.11,
6﹒ Effects of Electrospinning Gelatin Nanofibers with additives of Curcumin and Lithospermum on Skin Tissue Repair of Diabetic Rats,Perspectives on skin cancer prevention,Les Diablerets, Switzerland,2018.4.8 ~ 2018.4.11,
7﹒ Up-regulation of DDB2 by ERα confers to chemoresistance,EMBO Conference: THE DNA DAMAGE RESPONSE IN CELL PHYSIOLOGY AND DISEASE,Grecotel Cape Sounio, Greece,2017.10.2 ~ 2017.10.6,
8﹒ THE COMBINATION OF SGLT1 INHIBITORS CIRCUMVENTS ACQUIRED RESISTANCE TO EGFR TKIS IN NSCLC,ISCaM2016 (International Society of Cancer Metabolism),Belgium,2016.10.26 ~ 2016.10.29,
9﹒ Deficiency of LKB1/AMPK signaling by cigarette smoking reduces sensitivity of non-small cell lung cancer cells to EGFR TKIs,Best of ASCO 2016-2nd SSO Annual Scientific Meeting,Signapore,2016.7.8 ~ 2016.7.10,
10﹒ Lapatinib increases motility of triple-negative breast cancer cells by decreasing MiRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6,2015 台北國際乳癌研討會,張榮發基金會11樓國際會議廳,2015.9.12 ~ 2015.9.13,
11﹒ ERK at HER2 Thr701 negatively regulates HER2/AKT axis activation through reducing EGFR/HER2 dimerization in a clathrin-dependent manner.,Conference: Posttranslational Modification Networks,香港科技大學,2015.7.5 ~ 2015.7.10,
12﹒ Lapatinibenhances migration ability of triple-negative breast cancer cells through induction of Raf-1/MAPK-dependent interleukin-6 expression by downergulationof microRNA-7,美洲華人生物科學學會第15屆國際學術研討會,中央研究院,2015.6.26 ~ 2015.6.29,
13﹒ HBx sensitizes HCC cell lines to lapatinib by up-regulating ErbB3,美洲華人生物科學學會第15屆國際學術研討會,中央研究院,2015.6.26 ~ 2015.6.29,
14﹒ Suppression of maspin by IKKα-dependent microRNAs contributes to HBx-mediated human hepatocellular carcinoma progression,美洲華人生物科學學會第15屆國際學術研討會,中央研究院,2015.6.26 ~ 2015.6.29,
15﹒ Feedback phosphorylation by ERK at HER2 Thr701 negatively regulates HER2/AKT axis activation through reducing EGFR/HER2 dimerization in a clathrin-dependent manner.,EUROPHOSPHATASE 2015 EMBO conference,芬蘭,圖爾克,2015.6.24 ~ 2015.6.29,
16﹒ HER2 upregulates PD-L1 expression through PI3K-Akt pathway,第20屆台灣癌症聯合學術年會,台北榮總,2015.5.2 ~ 2015.5.3,
17﹒ Pim kinase inhibitors possess anticancer properties through downregulation of EGFR family in HER2-positive cancer cells,2015 生物醫學聯合學術年會,國防醫學院,2015.3.21 ~ 2015.3.22,
18﹒ ERK-mediated HER2 Thr701 phosphorylation negatively regulates HER2/AKT axis activation through reducing EGFR/HER2 dimerization in a clathrin-dependent manner,2014 Asian Breast Cancer Conference,台北國際會議中心,2014.10.17 ~ 2014.10.19,
19﹒ MicroRNA-221/222 confers lapatinib resistance through targeting p27kip1 expression.,2014 Asian Breast Cancer Conference,台北國際會議中心,2014.10.17 ~ 2014.10.19,
20﹒ TrichostatinA Suppresses EGFR Expression through Induction of MicroRNA-7 in an HDAC-Independent Manner in Lapatinib-Treated Cells,50th EMBO conference-cellular signalling and cancer therapy,Cavtat, Croatia,2014.5.23 ~ 2014.5.27,
21﹒ Lapatinib induces IL-6 expression via MAPK pathway in triple-negative breast cancer cells,50th EMBO conference-cellular signalling and cancer therapy,Cavtat, Croatia,2014.5.23 ~ 2014.5.27,
22﹒ ERK-mediated HER2 Thr701 phosphorylation negatively regulates HER2/AKT axis activation through reducing EGFR/HER2 dimerization in a clathrin-dependent manner,50th EMBO conference-cellular signalling and cancer therapy,Cavtat, Croatia,2014.5.23 ~ 2014.5.27,
23﹒ Suppression of Maspin by IKKα-dependent MicroRNAs Confer HBx-mediated Hepatocellular Cancer Progression,50th EMBO conference-cellular signalling and cancer therapy,Cavtat, Croatia,2014.5.23 ~ 2014.5.27,
24﹒ Lapatinib induces IL-6 expression via MAPK pathway in triple-negative breast cancer cells,2014 American Association for Cancer Research,San Diego,CA,2014.4.5 ~ 2014.4.9,
25﹒ Proteasome inhibitors overcome lapatinib resistance by downregulation of HER family,第29屆生物醫學聯合學術年會,國防醫學院,2014.3.15 ~ 2014.3.16,
26﹒ Suppression of Maspin by IKKα-dependent MicroRNAs Confer HBx-mediated Hepatocellular Cancer Progression,第29屆生物醫學聯合學術年會,國防醫學院,2014.3.15 ~ 2014.3.16,
27﹒ EGFR突變型的過度表現經由活化TENASCIN-C增加頭頸部鱗狀上皮癌細胞的侵犯力與降低癌瘲病人存活率,台灣耳鼻喉科醫學會第95屆學術演講會,台大醫院國際會議中心,2013.12.7 ~ 2013.12.8,
28﹒ IKKα-dependent MicroRNA Elevation Confers HBx-mediated Hepatocellular Tumor Progression through Suppression of Maspin,2013 International Symposium on Clinical and Translational Cancer Research,台北榮總,2013.9.28 ~ 2013.9.28,
29﹒ Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors,2013 International Symposium on Clinical and Translational Cancer Research,台北榮總,2013.9.28 ~ 2013.9.28,
30﹒ Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer Cells,2013 International Symposium on Clinical and Translational Cancer Research,台北榮總,2013.9.28 ~ 2013.9.28,
31﹒ OFF-TARGET ACTIVITY OF LAPATINIB SENSITIZES TRIPLE-NEGATIVE BREAST CANCER CELLS TO PROTEASOME INHIBITORS THROUGH ACTIVATION OF NF-κB IN A SFK-DEPENDENT MANNER,11th International Congress on Target Anticancer Therapies,Paris, France,2013.3.4 ~ 2013.3.6,
32﹒ Elevation of Histone deacetylase mediates lapatinib-induced cell mobility of triple-negative breast cancer cells through COX-2 overexpression.,The EMBO Meeting 2012,NICE, FRANCE,2012.9.22 ~ 2012.9.25,
33﹒ Kinase-inactive EGFR stabilizes COX-2 mRNA to mediate lapatinib-promoted aggressiveness of triple-negative breast cancer cells,國際癌症轉譯醫學研究學術研討會暨第十五屆台灣癌症臨床研究合作組織年會,中央研究院人文社會科學館國際會議廳,2011.11.20 ~ 2011.11.21,
34﹒ Elevation of Histone Deacetylase-3 and -7 Mediates Lapatinib-induced Cell Migration and Invasion of Triple-negative Breast Cancer Cells through COX-2 Overexpression,國際癌症轉譯醫學研究學術研討會暨第十五屆台灣癌症臨床研究合作組織年會,中央研究院人文社會科學館國際會議廳,2011.11.20 ~ 2011.11.21,
35﹒ ,李鎮源院逝世十周年學術研討會,台灣大學醫學院,2011.10.8 ~ 2011.10.8,Molecular Mechanism of Resistance to EGFR/HER2 TKIs
36﹒ Nuclear IKKalpha confers HBx-mediated migration of Hepatoma cells,36th FEBS CONGRESS Biochemistry for Tomorrow’s Medicine,TORINO, Italy,2011.6.25 ~ 2011.6.30,
37﹒ ,The 25th Joint Annual Conference of Biomedical Science,Taipei, Taiwan,2010.3.25 ~ 2010.3.26,Lapatinib facilitates the migration of HER2neg/low breast cancer cells via EGFR/COX-2 overexpression in a miR-7-dependent manner
38﹒ Akt facilitates the nuclear translocation of IKKalpha,8th Joint Conference of the AACR and JCA,Waikoloa, HI, USA,2010.2.5 ~ 2010.2.9,
39﹒ Akt facilitates the nuclear translocation of IKKalpha,The Epigenetics Annual Scientific Conference 2009,Melbourne, Australia,2009.12.1 ~ 2009.12.4,
40﹒ Lapatinib enhances cell migration of breast cancer cell via down-regulating miR-7,Epigenetics 2009 Australian Scientific Conferece,Melbourne, Australia,2009.12.1 ~ 2009.12.4,
41﹒ Inhibition of IKK activity enhances cell cycle arrest through p53-dependent p21Cip/WAF1 activation.,2008 Annual meeting of America Association for Cancer Research.,San Diego, CA, USA,2008.4.12 ~ 2008.4.16,
42﹒ Phosphorylation of CBP by IKKα promotes cell growth through switching its binding preference from p53 to NF-κB.,2007 AACR Annual Meeting,Los Angeles, CA,2007.4.14 ~ 2007.4.18,
43﹒ Role of nuclear IkB kinase (IKK) in tumorigenesis: phosphorylation and functional regulation of CREB-binding protein (CBP),IUBMB 50th Anniversary Symposium,Budapest, Hungary,2005.7.2 ~ 2005.7.5,
44﹒ ,Mini - Symposium on Cell Signaling and Gene Regulation,Tainan, Taiwan,2004.11.23 ~ 2004.11.23,Akt phosphorylation of p300 at Ser-1834 is essential for its HAT and transcriptional activity
45﹒ PI3K/Akt stimulates HAT activity of p300 and enhances its recruitment to ICAM-1 promoter,2004 ASBMB Annual Meeting and 8th IUBMB Conference,Boston, USA,,2004.6.12 ~ 2004.6.18,
 
研究計畫/Research Grant
(研究類型,研究計畫代號,主持人,補助或委託單位名稱,計畫名稱,研究經費,計畫期間)
1﹒ 個別型,MOST 111-2320-B-039-027-MY3,黃偉謙(Huang, Wei-Chien),吳永昌(Yang-Chang Wu),國科會,以中草藥活性成分發展葡萄糖轉運蛋白3抑制劑應用於肺癌治療之研究,$1600000,2024.8.1 ~ 2025.7.31
2﹒ 個別型,MOST 111-2314-B-039-043-MY3,黃偉謙(Huang, Wei-Chien),陳雅惠(Ya-Huey Chen)、湯智昕(Chih-Hsin Tang),國科會,探討代謝重組參與EZH2調控間質幹細胞分化之研究,$1406000,2024.8.1 ~ 2025.7.31
3﹒ 個別型,MOST 111-2320-B-039-027-MY3,黃偉謙(Huang, Wei-Chien),吳永昌(Yang-Chang Wu),國科會,以中草藥活性成分發展葡萄糖轉運蛋白3抑制劑應用於肺癌治療之研究,$1600000,2023.8.1 ~ 2024.7.31
4﹒ 個別型,MOST 111-2314-B-039-043-MY3,黃偉謙(Huang, Wei-Chien),陳雅惠(Ya-Huey Chen)、湯智昕(Chih-Hsin Tang),國科會,探討代謝重組參與EZH2調控間質幹細胞分化之研究,$1406000,2023.8.1 ~ 2024.7.31
5﹒ 個別型,CMUHCH-DMR-112-003,何建宜(Chien-Yi Ho),黃偉謙(Huang, Wei-Chien),附醫院內計畫,艾草中成分藉由抑制TMPRSS2表現具抗乳癌效果之探討,$500000,2022.9.1 ~ 2023.8.31
6﹒ 個別型,MOST 111-2320-B-039-027-MY3,黃偉謙(Huang, Wei-Chien),吳永昌(Yang-Chang Wu),國科會,以中草藥活性成分發展葡萄糖轉運蛋白3抑制劑應用於肺癌治療之研究,$1600000,2022.8.1 ~ 2023.7.31
7﹒ 個別型,MOST 111-2314-B-039-043-MY3,黃偉謙(Huang, Wei-Chien),陳雅惠(Ya-Huey Chen)、湯智昕(Chih-Hsin Tang),國科會,探討代謝重組參與EZH2調控間質幹細胞分化之研究,$1406000,2022.8.1 ~ 2023.7.31
8﹒ 個別型,MOST 111-2320-B-039-036,何建宜(Chien-Yi Ho),黃偉謙(Huang, Wei-Chien),國科會,艾草中成分藉由抑制TMPRSS2表現具抗乳癌效果之探討,$1300000,2022.8.1 ~ 2023.7.31
9﹒ 個別型,DMR-112-035,黃至豪(Huang ChihHao),黃偉謙(Huang, Wei-Chien),附醫院內計畫,代謝重新編程影響癌幹細胞功能參與乳癌早發與惡化之角色探討,$400000,2022.8.1 ~ 2023.7.31
10﹒ 個別型,DMR-112-021,陳家弘(Chia-Hung Chen),黃偉謙(Huang, Wei-Chien),附醫院內計畫,LKB1甲基化對非小細胞肺癌免疫監控的角色探討,$400000,2022.8.1 ~ 2023.7.31
11﹒ 個別型,DMR-111-120,黃偉謙(Huang, Wei-Chien),附醫院內計畫,DDB2對於乳癌化療藥物敏感性之探討,$330000,2022.8.1 ~ 2023.7.31
12﹒ 個別型,DMR-111-042,黃偉謙(Huang, Wei-Chien),附醫院內計畫,青蒿和艾草中新穎抗癌成分之分析與驗證,$300000,2021.8.1 ~ 2022.7.31
13﹒ 個別型,CMUHCH-DMR-110-003,何建宜(Chien-Yi Ho),黃偉謙(Wei-Chien Huang),附醫院內計畫,蝸牛黏液應用電紡奈米纖維緩釋的抗癌效果探討,$500000,2020.12.1 ~ 2021.9.30
14﹒ 個別型,CMUHCH-DMR-110-006,何建宜(Chien-Yi Ho),黃偉謙(Wei-Chien Huang),附醫院內計畫,三陰性乳腺癌化療增敏劑之研究,$395000,2020.11.1 ~ 2021.10.31
15﹒ 個別型,MOST 109-2327-B-039-003-,洪明奇(Mien-Chie Hung),黃偉謙(Wei-Chien Huang)、田霓(Ni Tien),國科會,COVID-19之標靶藥物開發,$5000000,2020.10.1 ~ 2021.8.31
16﹒ 個別型,MOST 109-2314-B-039-015,何建宜(Chien-Yi Ho),黃偉謙(Wei-Chien Huang),國科會,蝸牛黏液應用電紡奈米纖維緩釋的抗癌效果探討,$1310000,2020.8.1 ~ 2021.7.31
17﹒ 個別型,MOST 109-2320-B-039-014,黃偉謙(Wei-Chien Huang),葉名焮,國科會,非編碼核醣核酸參與HER2/EZH2 訊息路徑引發癌症轉移之角色探討,$1380000,2020.8.1 ~ 2021.7.31
18﹒ 個別型,CMU108-MF-85,黃偉謙(Wei-Chien Huang),本校(含附醫),DDB2 調控HBX引發化療抗性之探討,$300000,2019.9.9 ~ 2020.7.31
19﹒ 個別型,DMR-109-132,黃偉謙(Wei-Chien Huang),涂智彥(Chih-Yen Tu),附醫院內計畫,SGLT1表現增加參與肺癌細胞對EGFR TKI產生繼發性抗藥性之影響,$500000,2019.8.1 ~ 2020.7.31
20﹒ 個別型,DMR-109-021,涂智彥(Chih-Yen Tu),黃偉謙(Wei-Chien Huang),附醫院內計畫,能量代謝改變對於EGFR TKI抗藥性之角色探討,$400000,2019.8.1 ~ 2020.7.31
21﹒ 個別型,DMR-109-022,陳家弘(Chia-Hung Chen),黃偉謙(Wei-Chien Huang),附醫院內計畫,葡萄糖代謝調控非小細胞肺癌表現免疫檢查點分子之研究,$400000,2019.8.1 ~ 2020.7.31
22﹒ 個別型,MOST 108-2314-B-039-032-,黃偉謙(Wei-Chien Huang),國科會,LincRNA-p21參與HBx引發化療抗藥性之探討,$1000000,2019.8.1 ~ 2020.7.31
23﹒ 個別型,MOST 108-2314-B-039-056-,涂智彥(Chih-Yen Tu),黃偉謙(Wei-Chien Huang),國科會,葡萄糖代謝對於抽煙誘發EGFR TKI抗藥性之角色探討,$1130000,2019.8.1 ~ 2020.7.31
24﹒ 個別型,MOST 108-2314-B-039-053-,陳家弘(Chia-Hung Chen),黃偉謙(Wei-Chien Huang),國科會,吸菸透過代謝失調影響非小細胞肺癌上免疫檢查點分子的表現與功能,$1150000,2019.8.1 ~ 2020.7.31
25﹒ 個別型,CMU107-TU-06,黃偉謙(Wei-Chien Huang),本校(含附醫),Deficiency of energy sensing LKB1/AMPK pathway by cigarette smoking reduces sensitivity of NSCLCs to EGFR TKIs,$900000,2019.6.1 ~ 2020.7.31
26﹒ 個別型,MOST 105-2320-B-039-056-MY3,黃偉謙(Wei-Chien Huang),葉名焮,國科會,長鏈非編碼核糖核酸LincRNA-p21影響抗癌藥物敏感性之探討,$1305000,2018.8.1 ~ 2019.7.31
27﹒ 個別型,MOST 105-2314-B-039-035-MY3,涂智彥(Chih-Yen Tu),黃偉謙(Wei-Chien Huang),國科會,線香燃燒煙霧對肺癌發展與治療之角色探討,$1400000,2018.8.1 ~ 2019.7.31
28﹒ 個別型,DMR-108-012,黃偉謙(Wei-Chien Huang),附醫院內計畫,絲胺酸-單碳代謝途徑於吸菸引發非小細胞肺癌增生的角色探討,$257732,2018.8.1 ~ 2019.7.31
29﹒ 個別型,DMR-108-029,黃偉謙(Wei-Chien Huang),附醫院內計畫,吸菸透過代謝失調影響非小細胞肺癌上免疫檢查點分子及分泌蛋白體的表現,$206186,2018.8.1 ~ 2019.7.31
30﹒ 個別型,DMR-108-100,黃偉謙(Wei-Chien Huang),附醫院內計畫,吸菸影響葡萄糖代謝與肺癌惡化之探討,$360825,2018.8.1 ~ 2019.7.31
31﹒ 學生參與計畫,CMU106-SR-24,黃偉謙(Wei-Chien Huang),本校(含附醫),抽煙影響非小細胞肺癌中葡萄糖代謝之探討,$35000,2017.8.1 ~ 2018.2.28
32﹒ 個別型,DMR-107-023,陳家弘(Chen, Chia-Hung),黃偉謙(Huang, Wei-Chien),附醫院內計畫,ERK負回饋調控HER2活性 之探討,$500000,2017.8.1 ~ 2018.7.31
33﹒ 個別型,DMR-107-029,黃偉謙(Huang, Wei-Chien),涂智彥(Tu, Chih-Yen),附醫院內計畫,LincRNA-p21參與HBx蛋白誘發肝癌對化學治療產生抗藥性之探討,$400000,2017.8.1 ~ 2018.7.31
34﹒ 個別型,DMR-107-030,黃偉謙(Huang, Wei-Chien),附醫院內計畫,絲氨酸磷酸化調控HER2活性之探討,$154639,2017.8.1 ~ 2018.7.31
35﹒ 個別型,MOST 105-2314-B-039-035-MY3,涂智彥(Tu, Chih-Yen),黃偉謙(Huang, Wei-Chien),國科會,線香燃燒煙霧對肺癌發展與治療之角色探討,$1400000,2017.8.1 ~ 2018.7.31
36﹒ 個別型,MOST 105-2320-B-039-056-MY3,黃偉謙(Wei-Chien Huang),葉名焮,國科會,長鏈非編碼核糖核酸LincRNA-p21影響抗癌藥物敏感性之探討,$1515000,2017.8.1 ~ 2018.7.31
37﹒ 整合型(召集人、總主持人),CMU106-ASIA-18,黃偉謙(Wei-Chien Huang),何建宜(Chien-Yi Ho)、王建國,本校(含附醫),過敏、慢性發炎與癌症研究平台,$500000,2017.8.1 ~ 2018.7.31
38﹒ 學生參與計畫,106-2813-C-039-024-B,黃偉謙,國科會,抽煙影響非小細胞肺癌中葡萄糖代謝之探討,$48000,2017.7.1 ~ 2018.2.28
39﹒ 學生參與計畫,CMU105-SR-51,黃偉謙(Wei-Chien Huang),本校(含附醫),HER2絲胺酸磷酸化於產生lapatinib抗藥性之角色探討,$35000,2016.8.1 ~ 2017.2.28
40﹒ 個別型,MOST 105-2320-B-039-056-MY3,黃偉謙(Wei-Chien Huang),葉名焮,國科會,長鏈非編碼核糖核酸LincRNA-p21影響抗癌藥物敏感性之探討,$1480000,2016.8.1 ~ 2017.7.31
41﹒ 個別型,MOST 105-2314-B-039-035-MY3,涂智彥(Chih-Yen Tu),黃偉謙(Wei-Chien Huang),國科會,線香燃燒煙霧對肺癌發展與治療之角色探討,$1400000,2016.8.1 ~ 2017.7.31
42﹒ 學生參與計畫,105-2815-C-039-052-B,黃偉謙(Wei-Chien Huang),國科會,HER2絲胺酸磷酸化於產生lapatinib抗藥性之角色探討,$48000,2016.7.1 ~ 2017.2.28
43﹒ 整合型項下子計畫(主持人),MOST 105-2911-I-002-302,邱昌芳(Chang-Fang Chiu),蔡輔仁(Fuu-Jen Tsai)、吳永昌(Yang-Chang Wu)、黃偉謙(Wei-Chien Huang)、張為超(Wei-Chao Chang)、王紹椿(Shao-Chun Wang),國科會,跨國頂尖研究中心-跨國頂尖癌症研究中心(5/5),$15000000,2016.2.1 ~ 2017.1.31
44﹒ 整合型(召集人、總主持人),MOHW105-TDU-B-212-124-002,趙坤山(Kun-San Chao),邱昌芳(Chang-Fang Chiu)、劉良智(Liu, Liang-Chih)、洪明奇(Mien-Chie Hung)、余永倫(Yung-Luen Yu)、黃偉謙(Wei-Chien Huang)、林柏翰(Po-Han Lin)、佘玉萍(Yuh-Pyng Sher)、王惠暢(Hwei-Chung Wang)、葛應欽(Ying-Chin Ko),衛福部,衛生福利部第二期105年度癌症研究計畫-中國醫藥大學附設醫院,$30000000,2016.1.1 ~ 2016.12.31
45﹒ 個別型,NHRI-EX105-10329BI,黃偉謙(Wei-Chien Huang),國衛院,HER2調控 EZH2 表現於乳癌發展之角色探討,$1500000,2016.1.1 ~ 2016.12.31
46﹒ 整合型項下子計畫(主持人),MOST 104-2320-B-039-001,黃偉謙(Wei-Chien Huang),國科會,EGFR訊息傳遞與癌細胞代謝調控之交互作用探討-葡萄糖吸收與內質網壓力影響EGFR TKIs 抗癌效果之角色探討(3/3),$1200000,2015.8.1 ~ 2016.7.31
47﹒ 個別型,CMU104-S-01,黃偉謙(Wei-Chien Huang),本校(含附醫),EZH2於HER2陽性乳癌幹細胞中之角色探討,$300000,2015.8.1 ~ 2016.7.31
48﹒ 個別型,MOST 104-2811-B-039-019,陳韻如,黃偉謙,國科會,LKB1/AMPK 能量調節路徑於 EGFR TKI 抗腫瘤作用之角色探討,$1570000,2015.8.1 ~ 2016.7.31
49﹒ 非研究型計畫 (例如:課程計畫),MOST-104-2922-I-039-009,黃偉謙,國科會,赴奧地利維也納(Vienna)參加第五十屆國際肝癌會議,$30000,2015.4.10 ~ 2015.5.11
50﹒ 個別型,NHRI-EX104-10329BI,黃偉謙(Wei-Chien Huang),國衛院,HER2調控 EZH2 表現於乳癌發展之角色探討,$1218000,2015.1.1 ~ 2015.12.31
51﹒ 個別型,CMU103-MOST-01,黃偉謙(Wei-Chien Huang),本校(含附醫),香煙萃取物引發c-MET表現於肺癌進程之角色探討,$100000,2014.9.1 ~ 2015.7.31
52﹒ 非研究型計畫 (例如:課程計畫),MOST 103-2912-I-039-506,黃偉謙(Wei-Chien Huang),國科會,邀請UT Southwestern Medical School Jer Tsong Hsieh教授,$44625,2014.8.15 ~ 2014.10.1
53﹒ 學生參與計畫,CMU103-SR-41,黃偉謙(Wei-Chien Huang),本校(含附醫),HER2 蛋白激?非依賴性之功能,$35000,2014.8.1 ~ 2015.2.28
54﹒ 整合型項下子計畫(主持人),MOST 103-2320-B-039-001,黃偉謙(Wei-Chien Huang),國科會,EGFR訊息傳遞與癌細胞代謝調控之交互作用探討-葡萄糖吸收與內質網壓力影響EGFR TKIs 抗癌效果之角色探討(2/3),$1320000,2014.8.1 ~ 2015.7.31
55﹒ 個別型,MOST 103-2314-B-039-027,葉名焮,黃偉謙(Wei-Chien Huang),國科會,Lapatinib 脫靶效應增強HDAC抑制劑對三陰性乳癌治療效果之探討,$1270000,2014.8.1 ~ 2015.7.31
56﹒ 學生參與計畫,MOST 103-2815-C-039-041-B,黃偉謙(Wei-Chien Huang),國科會,HER2 蛋白激?非依賴性之功能,$47000,2014.7.1 ~ 2015.2.28
57﹒ 非研究型計畫 (例如:課程計畫),NSC 103-2811-B-039-001,黃偉謙(Wei-Chien Huang),國科會,LKB1/AMPK 能量調節路徑於 EGFR TKI 抗腫瘤作用之角色探討,$500556,2014.1.1 ~ 2014.7.31
58﹒ 個別型,NHRI-EX103-10329BI,黃偉謙(Wei-Chien Huang),國衛院,HER2調控 EZH2 表現於乳癌發展之角色探討,$1270000,2014.1.1 ~ 2014.12.31
59﹒ 學生參與計畫,CMU102-SR-26,黃偉謙(Wei-Chien Huang),本校(含附醫),4D PETCT評估呼吸運動與腫瘤位置對胸腔腫瘤PET造影的影響,$35000,2013.8.1 ~ 2014.2.28
60﹒ 學生參與計畫,CMU102-SR-45,黃偉謙(Wei-Chien Huang),本校(含附醫),利用Lapatinib脫靶效應增強HDAC抑制劑治療三陰性乳癌效果之探討,$35000,2013.8.1 ~ 2014.2.28
61﹒ 個別型,NSC 102-2320-B-039-054-MY3,黃偉謙(Wei-Chien Huang),陳韻如,國科會,LKB1/AMPK 能量調節路徑於 EGFR TKI 抗腫瘤作用之角色探討,$1570000,2013.8.1 ~ 2014.7.31
62﹒ 整合型項下子計畫(主持人),NSC 102-2320-B-039-052,黃偉謙(Wei-Chien Huang),國科會,EGFR訊息傳遞與癌細胞代謝調控之交互作用探討-葡萄糖吸收與內質網壓力影響EGFR TKIs 抗癌效果之角色探討(1/3),$1200000,2013.8.1 ~ 2014.7.31
63﹒ 學生參與計畫,NSC 102-2815-C-039-115-B,黃偉謙(Wei-Chien Huang),國科會,利用Lapatinib脫靶效應增強HDAC抑制劑治療三陰性乳癌效果之探討,$47000,2013.7.1 ~ 2014.2.28
64﹒ 學生參與計畫,NSC 102-2815-C-039-096-B,黃偉謙(Wei-Chien Huang),國科會,4D PETCT評估呼吸運動與腫瘤位置對胸腔腫瘤PET造影的影響,$47000,2013.7.1 ~ 2014.2.28
65﹒ 個別型,DMR-102-113,葉名焮(Ming-Hsin, Alex, Yeh),黃偉謙(Wei-Chien Huang),附醫院內計畫,Lapatinib 脫靶效應增強HDAC抑制劑對三陰性乳癌治療效果之探討,$300000,2013.2.1 ~ 2013.12.31
66﹒ 整合型(召集人、總主持人),NSC 102-2911-I-002-303,陳志毅(Chih-Yi Chen),吳永昌(Yang-Chang Wu)、蔡輔仁(Fuu-Jen Tsai)、陳孟良(Mong-Liang Chen)、黃偉謙(Wei-Chien Huang)、張為超(Wei-Chao Chang)、邱昌芳(Chang-Fang Chiu),國科會,跨國頂尖癌症研究中心(2/5),$15000000,2013.2.1 ~ 2014.1.31
67﹒ 整合型項下子計畫(主持人),NSC 99-2632-B-039-001-MY3,洪明奇(Mien-Chie Hung),余永倫(Yung-Luen Yu)、蘇振良(Jen-Liang Su)、黃偉謙(Wei-Chien Huang)、李龍緣(Long-Yuan Li)、宋賢穎(Shian-Ying Sung)、謝嘉玲(Chia-Ling Hsieh)、劉哲育(Liu Jer-Yuh),國科會,腫瘤發展之訊息傳遞路徑-腫瘤發展之訊息傳遞路徑,$8000000,2012.8.1 ~ 2013.7.31
68﹒ 個別型,NSC 101-2320-B-039-049,黃偉謙(Wei-Chien Huang),陳韻如,國科會,EZH2蛋白表現調節與lapatinib抗藥性形成之探討,$1125000,2012.8.1 ~ 2013.7.31
69﹒ 個別型,CMU101-NSC-01,黃偉謙(Wei-Chien Huang),本校(含附醫),高解析肺通氣影像與腫瘤治療計畫應用,$100000,2012.8.1 ~ 2013.7.31
70﹒ 整合型項下子計畫(主持人),NSC 101-2911-I-002-303,陳志毅(Chih-Yi Chen),邱昌芳(Chang-Fang Chiu)、蔡輔仁(Fuu-Jen Tsai)、吳永昌(Yang-Chang Wu)、陳孟良(Mong-Liang Chen)、黃偉謙(Wei-Chien Huang)、張為超(Wei-Chao Chang),國科會,跨國頂尖癌症研究中心,$15000000,2012.2.1 ~ 2013.1.31
71﹒ 個別型,NHRI-EX101-9812BC,黃偉謙(Wei-Chien Huang),洪明奇(Mien-Chie Hung),國衛院,IKKKalpha於細胞核內參與腫瘤發展及轉移之探討,$1590000,2012.1.1 ~ 2012.12.31
72﹒ 整合型項下子計畫(主持人),NSC 99-2632-B-039-001-MY3,洪明奇(Mien-Chie Hung),余永倫(Yung-Luen Yu)、蘇振良(Jen-Liang Su)、黃偉謙(Wei-Chien Huang)、李龍緣(Long-Yuan Li)、宋賢穎(Shian-Ying Sung)、謝嘉玲(Chia-Ling Hsieh)、劉哲育(Liu Jer-Yuh),國科會,腫瘤發展之訊息傳遞路徑-腫瘤發展之訊息傳遞路徑,$8000000,2011.8.1 ~ 2012.7.31
73﹒ 個別型,CMU100-NSC-09,黃偉謙(Wei-Chien Huang),本校(含附醫),異質性HER2表現對lapatinib抗癌效果之影響,$200000,2011.8.1 ~ 2012.7.31
74﹒ 個別型,NSC 100-2320-B-039-021-,夏德椿(Te-Chun Hsia),黃偉謙(Wei-Chien Huang),國科會,BCRP表現影響EGFR抑制劑治療效果之探討,$710000,2011.8.1 ~ 2012.7.31
75﹒ 個別型,NSC100-2320-B-039-022-,涂智彥(Chih-Yen Tu),黃偉謙(Wei-Chien Huang),國科會,異質性HER2表現對lapatinib抗癌效果之影響,$910000,2011.8.1 ~ 2012.7.31
76﹒ 非研究型計畫 (例如:課程計畫),NSC 100-2922-I-039-007,黃偉謙(Wei-Chien Huang),國科會,赴義大利Torino (Turin) 都靈參加36屆歐洲生化聯盟會議,$30000,2011.6.8 ~ 2011.7.15
77﹒ 國家型,NSC 100-3112-B-039-006,黃偉謙(Wei-Chien Huang),洪明奇(Mien-Chie Hung),國科會,鈉葡萄糖共轉運載體影響肺癌表皮生長因子受體標靶治療效能之研究,$2290000,2011.5.1 ~ 2012.4.30
78﹒ 個別型,NHRI-EX100-9812BC,黃偉謙(Wei-Chien Huang),洪明奇(Mien-Chie Hung),國衛院,IKKKalpha於細胞核內參與腫瘤發展及轉移之探討,$1799000,2011.1.1 ~ 2011.12.31
79﹒ 個別型,NSC 97-2320-B-039-033-MY3,黃偉謙(Wei-Chien Huang),洪明奇(Mien-Chie Hung),國科會,HER-2核易位與癌細胞對EGFR抑制劑產生耐藥性之探討,$1970000,2010.8.1 ~ 2011.7.31
80﹒ 整合型項下子計畫(主持人),NSC 99-2632-B-039-001-MY3,洪明奇(Mien-Chie Hung),余永倫(Yung-Luen Yu)、蘇振良(Jen-Liang Su)、黃偉謙(Wei-Chien Huang)、李龍緣(Long-Yuan Li)、宋賢穎(Shian-Ying Sung)、謝嘉玲(Chia-Ling Hsieh)、劉哲育(Liu Jer-Yuh),國科會,腫瘤發展之訊息傳遞路徑-腫瘤發展之訊息傳遞路徑,$8000000,2010.8.1 ~ 2011.7.31
81﹒ 整合型(召集人、總主持人),CMU99-NSC-09,洪明奇(Mien-Chie Hung),李龍緣(Long-Yuan Li)、謝嘉玲(Chia-Ling Hsieh)、宋賢穎(Shian-Ying Sung)、余永倫(Yung-Luen Yu)、黃偉謙(Wei-Chien Huang)、蘇振良(Jen-Liang Su)、劉哲育(Liu Jer-Yuh),本校(含附醫),腫瘤發展之訊息傳遞路徑-腫瘤發展之訊息傳遞路徑,$2000000,2010.8.1 ~ 2011.7.31
82﹒ 國家型,NSC 99-3112-B-039-002,黃偉謙(Wei-Chien Huang),洪明奇(Mien-Chie Hung),國科會,鈉葡萄糖共轉運載體影響肺癌表皮生長因子受體標靶治療效能之研究(2/2),$2290000,2010.5.1 ~ 2011.4.30
83﹒ 個別型,NHRI-EX99-9812BC,黃偉謙(Wei-Chien Huang),洪明奇(Mien-Chie Hung),國衛院,IKKKALPHA於細胞核內參與腫瘤發展及轉移之探討,$1999000,2010.1.1 ~ 2010.12.31
84﹒ 國家型,NSC 98-3112-B-039-002,黃偉謙(Wei-Chien Huang),洪明奇(Mien-Chie Hung),國科會,鈉葡萄糖共轉運載體影響肺癌表皮生長因子受體標靶治療效能之研究(1/2),$2158000,2009.5.1 ~ 2010.4.30
85﹒ 個別型,NHRI-EX98-9812BC,黃偉謙(Wei-Chien Huang),洪明奇(Mien-Chie Hung),國衛院,IKKKALPHA於細胞核內參與腫瘤發展及轉移之探討,$1999000,2009.1.1 ~ 2009.12.31
86﹒ 個別型,NSC 97-2320-B-039-033-MY3,黃偉謙(Wei-Chien Huang),洪明奇(Mien-Chie Hung),國科會,HER-2核易位與癌細胞對EGFR抑制劑產生耐藥性之探討,$3940000,2008.8.1 ~ 2011.7.31
87﹒ 個別型,NSC 97-2320-B-039-033-MY3,黃偉謙(Wei-Chien Huang),洪明奇(Mien-Chie Hung),國科會,HER-2核易位與癌細胞對EGFR抑制劑產生耐藥性之探討,$1970000,2008.8.1 ~ 2009.7.31
88﹒ 個別型,NSC 97-2320-B-039-033-MY3,黃偉謙(Wei-Chien Huang),洪明奇(Mien-Chie Hung),國科會,HER-2核易位與癌細胞對EGFR抑制劑產生耐藥性之探討(促進短期就業措施-高正彥),$513492,2008.8.1 ~ 2009.7.31
 
專利/Patent
(專利名稱,專利類別,專利國別,專利號碼,專利期間)
1﹒ 評估拉怕替尼於肝癌療效的用法與ErbB3基因表現程度作為分子指標之用途,發明專利,台灣,I535852,2016.6.1 ~ 2034.2.18
2﹒ HBx基因表現程度作為分子指標之用途,發明專利,台灣,I522472,2016.2.21 ~ 2034.2.18
 
獲獎/Award
(獲獎名稱,給獎單位,獲獎日期)
1﹒ 醫學研究青年學者獎,李鎮源教授基金會,2007.11.10
2﹒ 台灣藥理學會年輕學者獎,台灣藥理學會,2006.03.18
3﹒ 第十四屆王民寧獎-國內醫藥研究所博士班優秀論文獎,財團法人王民寧先生紀念基金會,2004.12.15
4﹒ Graduate Travel Award,American Society for Biochemistry and Molecular Biology,2004.03.12